Vanguard Group Inc Athenex, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.12 - $0.21 $150 - $264	1,258 Added 0.02%	5,363,164 $804,000
Q3 2022 Nov 14, 2022	BUY	$0.24 - $1.11 $177,864 - $822,622	741,101 Added 16.04%	5,361,906 $1.45 Million
Q2 2022 Aug 12, 2022	BUY	$0.41 - $0.91 $295,729 - $656,374	721,291 Added 18.5%	4,620,805 $1.89 Million
Q1 2022 May 13, 2022	SELL	$0.79 - $1.59 $668,838 - $1.35 Million	-846,631 Reduced 17.84%	3,899,514 $3.23 Million
Q4 2021 Feb 14, 2022	BUY	$1.36 - $2.94 $257,340 - $556,309	189,221 Added 4.15%	4,746,145 $6.46 Million
Q3 2021 Nov 12, 2021	BUY	$2.97 - $4.84 $904,599 - $1.47 Million	304,579 Added 7.16%	4,556,924 $13.7 Million
Q2 2021 Aug 13, 2021	BUY	$3.71 - $5.13 $15.8 Million - $21.8 Million	4,252,345 New	4,252,345 $19.6 Million

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.